INMUNE BIO INC
INMBNASDAQ🏆 #3417 by market capUS Equity
$2.10▼ $0.03 (−1.41%)
Market closed · at close1h—
24h▼ 1.4%
7d▲ 10.8%
14d▲ 22.9%
30d▲ 13.2%
1y▼ 13.4%
🏦Market Cap
$56M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
1171.2x
Expensive
Otter Score
54
Weak
Trading Snapshot
- Day Range
- $2.07 – $2.11
- 52-Week Range
- $1.09 – $2.61
- Volume
- $2.80B
- Avg Volume
- $2.52B
- Shares Outstanding
- 26.6M
- Next Earnings
- Sep 16, 2026
Fundamentals Snapshot
- Annual Revenue
- $49,289
- Last Q Revenue
- $11,960
- P/E Ratio
- —
- P/S Ratio
- 1171.2x
- EPS (TTM)
- $-1.69
- Dividend Yield
- —
Why Investors Own INMB
- ✓High-growth profile — revenue up +58.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 74% gross margin and 17% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$49,289▲ +63.3% YoY
Gross Margin (TTM)
74.0%▲ +3.9% YoY
Operating Income (TTM)
$13,752▲ +63.3% YoY
Free Cash Flow (TTM)
$8,281▲ +63.3% YoY
About INMUNE BIO INC
A company profile for INMUNE BIO INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
54/100
Analyst Price Target
ⓘAverage Target
$2.66
▲ +27.0% Upside
High Target$3.04
Low Target$2.00
Based on 14 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
INMUNE BIO INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift INMB price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Barron’s·1d ago
INMUNE BIO INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.